Display options
Cite
Rubin DT, Cohen RD, Sandborn WJ, et al. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11(12):1510doi: 10.1093/ecco-jcc/jjx052.
Rubin, D. T., Cohen, R. D., Sandborn, W. J., Lichtenstein, G. R., Axler, J., Riddell, R. H., Zhu, C., Barrett, A. C., Bortey, E., & Forbes, W. P. (2017). Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. Journal of Crohn's & colitis, 11(12), 1510. https://doi.org/10.1093/ecco-jcc/jjx052
Rubin, David T, et al. "Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial." Journal of Crohn's & colitis vol. 11,12 (2017): 1510. doi: https://doi.org/10.1093/ecco-jcc/jjx052
Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Dec 04;11(12):1510. doi: 10.1093/ecco-jcc/jjx052. PMID: 28453665; PMCID: PMC5951008.
Copy Download .nbib Format: NLM
Share it on

J Crohns Colitis. 2017 Dec 04;11(12):1510. doi: 10.1093/ecco-jcc/jjx052.

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Journal of Crohn's & colitis

David T Rubin, Russell D Cohen, William J Sandborn, Gary R Lichtenstein, Jeffrey Axler, Robert H Riddell, Cindy Zhu, Andrew C Barrett, Enoch Bortey, William P Forbes

Affiliations

  1. Inflammatory Bowel Disease Center, University of Chicago Medicine, USA.
  2. Division of Gastroenterology, University of California [UC] San Diego and UC San Diego Health System, USA.
  3. Division of Gastroenterology, Perelman School of Medicine of the University of Pennsylvania, USA.
  4. Toronto Digestive Disease Associates, Canada.
  5. Department of Pathology and Laboratory Medicine, Mt Sinai Hospital, Canada.
  6. Salix Pharmaceuticals, USA.

PMID: 28453665 PMCID: PMC5951008 DOI: 10.1093/ecco-jcc/jjx052

[No abstract available.]

Publication Types